Gálvez, RafaelRibera, VictoriaGonzález-Escalada, José RamónSouto, AliciaCánovas, María LuzCastro, AndrésHerrero, BegoñaMaqueda, María de los ÁngelesCastilforte, MatildeMarco-Martínez, José JavierPérez, ConcepciónVicente-Fatela, LorenzaNieto, ConsueloOrduña, Maria JoséPadrol, AnnaReig, EnriqueCarballido, JoaquínCózar, José Manuel2012-11-232012-11-232008-08Galvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A et al. Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.Patient Prefer Adherence. 2008 Feb 2;2:215-24.1177-889X (Online)http://hdl.handle.net/10668/652Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis. Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire. Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment Discussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.esNeoplasias de la PróstataMetástasis de la NeoplasiaDolorDifosfonatosEstudios Multicéntricos como AsuntoMasculinoBone metastasisPainProstate cancerZoledronic acidMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation AgentsMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic NeoplasmsMedical Subject Headings::Diseases::Neoplasms::Neoplastic Processes::Neoplasm MetastasisMedical Subject Headings::Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Nervous System Physiological Processes::Sensation::PainMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organophosphorus Compounds::DiphosphonatesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as TopicMedical Subject Headings::Check Tags::MaleMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation AgentsMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation Agentsresearch article19920966open access10.2147/PPA.S2314PMC2770417